Mengchang Yang

Abstract To evaluate the efficacy and safety of NH600001, a novel etomidate derivative, in gastrointestinal endoscopy, as well as its impact on adrenocortical function, two multicenter, double-blind, randomized, controlled clinical trials(NH600001-21 [Phase II trial] and NH600001-31 [Phase III trial]) were conducted in China. In NH600001-21, 160 gastroscopy subjects were randomized 1:1:1:1 to receive NH600001 (0.20, 0.25, or 0.30 mg/kg) and etomidate (0.30 mg/kg).

Back to Journals » Drug Design, Development and Therapy » Volume 19 Authors Zhang H , Wang S, Yang M, Huang Y , Wang K, Jiang K , Luo F, Hu X , Hong Y, Huang F, Jin S , Qi F, Wang S, Zhang X, Luo H, Guo L, Zhang L , Li J, Chen Y, Qin Z, Chen C, Yang J , Jiang W, Fu N, Ju Y, Li Y , Wang J, Ouyang W, Feng Y Received 15 April 2025 Accepted for publication 15 August 2025 Published 3 September 2025 Volume 2025:19 Pages 7707—7718 DOI https://doi.org/10.2147/DDDT.S529526 Checked for plagiarism Yes...

Long non-coding RNAs (lncRNAs) play important roles in the malignant behavior of cancer. HOTAIR, a well-studied lncRNA, contributes to breast cancer development, and overexpression of HOTAIR predicts a poor prognosis. However, the regulatory role of HOTAIR in the cancer stem-like cell (CSC) subpopulation remains largely unknown.